## Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A process comprising:

applying an ophthalmic medicine or ophthalmic solution comprising a complex nutritive base to an eye of a human or an animal,

the base comprising at least consisting of a multiplicity of amino acids, vitamins, trace elements, and metallic salts and being free of any cellular growth factor or any biological extract of animal or cellular origin or any pharmaceutically active principle.

2. (Currently Amended) A process for treating an item that is designed to come into external contact with a cornea of an eye of a human or an animal, the process comprising:

treating the item with a treatment product comprising a complex nutritive base, the base comprising at least consisting of a multiplicity of amino acids, vitamins, trace elements, and metallic salts and being free of any cellular growth factor or any biological extract of animal or cellular origin or any pharmaceutically active principle.

- 3. (Previously Presented) The process as claimed in claim 1, wherein the ophthalmologic medicine or ophthalmologic solution consists of a trophic composition in an aqueous medium comprising the complex nutritive base, an inhibitor of collagenases of the human or animal corneal epithelium, and a promoter of neocollagen synthesis.
- 4. (Previously Presented) The process as claimed in claim 2, wherein the treatment product consists of a trophic composition in an aqueous medium comprising the complex nutritive base, an inhibitor of collagenases of the human or animal corneal epithelium, and a promoter of neocollagen synthesis.

- 5. (Previously Presented) The process as claimed in claim 3, wherein the trophic composition is formulated so as to establish a pH between 7.3 and 7.5 and an osmolarity between 300 and 350 Osm.
- 6. (Previously Presented) The process as claimed in claim 5, wherein the inhibitor of collagenases is selected from the group consisting of cysteine, N-acetylcysteine, and EDTA calcium salt.
- 7. (Previously Presented) The process as claimed in claim 5, wherein the inhibitor of collagenases is N-acetylcysteine.
- 8. (Previously Presented) The process as claimed in claim 5, wherein the inhibitor of collagenases represents at most 5% by weight of the trophic composition.
- 9. (Previously Presented) The process as claimed in claim 5, wherein the promoter of neocollagen synthesis is proline or hydroxyproline.
- 10. (Previously Presented) The process as claimed in claim 5, wherein the promoter of neocollagen synthesis represents at most 0.5% by weight of the trophic composition.
- 11. (Previously Presented) The process as claimed in claim 5, wherein the ophthalmologic solution comprises hyaluronic acid and/or a salt of hyaluronic acid in a total proportion by weight of the trophic composition of at most 0.1% and preferably 0.07%.
- 12. (Previously Presented) The process as claimed in claim 5, wherein the trophic composition includes a preservative in a proportion by weight of the composition of at most 0.0001%.
- 13. (Previously Presented) The process as claimed in claim 12, wherein the preservative is polyhexanide or polyhexamethylene biguanide.

## 14. (Previously Presented) The process as claimed in claim 12, wherein the trophic composition comprises the following components:

Concentration (mg/L)
q.s.
6800
1754.4
1160
1080
421.4
300
284
131.2
126.1
120.0
112
70.3
55
54
50
42
24
24
20.05
18
14.8

## Application No. 10/540,979

Asparagine	14.2
Methionine	13.5
Tyrosine	11.7
Phenylalanine	10.0
Tryptophan	9.3
Alanine	9.2
Glycine	7.6
Isoleucine	6.0
Aspartic acid	4.0
Sodium sulfate	3.4
Ferrous sulfate	0.003
Folic acid	0.8
Thymidine	0.73
Cyanocobalamin	0.41
Calcium antothenate	0.3
Thiamine HCl	0.3
Thioctic acid	0.3
Zinc sulfate	0.144
Sodium silicate	0.142
Pyrodixine HCl	0.06
Niacinamide	0.04
Riboflavin	0.3
Biotin	0.02
Copper sulfate	0.003
Ammonium molybdate	0.00120

Ammonium vanadate	0.003
Mn chloride	0.00002
Sodium hyaluronate	70
Polyhexanide or polyhexamethylene biguanide	0.1
n-acetylcysteine	500
Hydroxyproline or praline	35.

- 15. (Previously Presented) The process as claimed in claim 1, wherein the ophthalmologic medicine or ophthalmologic solution is in liquid form or in dry form for reconstitution with an aqueous medium.
- 16. (Previously Presented) The process as claimed in claim 2, wherein the treatment product is in liquid form or in dry form for reconstitution with an aqueous medium.
- 17. (Previously Presented) The process as claimed in claim 1, wherein the ophthalmologic medicine or ophthalmologic solution is in a form selected from the group consisting of drops or regenerating tears, comfort drops, eyewash, and solution.
- 18. (Previously Presented) The process as claimed in claim 1, wherein the ophthalmic solution is a comfort solution.
- 19. (Previously Presented) The process as claimed in claim 4, wherein the trophic composition is formulated so as to establish a pH between 7.3 and 7.5 and an osmolarity between 300 and 350 Osm.